期刊文献+

周剂量紫杉醇对局部晚期食管癌的放疗增敏作用 被引量:6

Radiosensitizing Effect of Weekly-dose Paclitaxel on Locally Advanced Esophageal Carcinoma
暂未订购
导出
摘要 目的探讨周剂量紫杉醇对局部晚期食管癌的放疗增敏作用。方法将44例不宜手术的局部晚期食管癌患者随机分为放疗增敏组和单纯放疗组,每组22例。2组放疗方法相同,均采用常规设野,常规分割外照射,总剂量60~66 Gy。放疗增敏组在放疗同期每周接受1次紫杉醇(40 mg.m-2)化疗,连用6周。结果 44例患者均可评价疗效,放疗增敏组与单纯放疗组有效率分别为86.4%和63.6%(P<0.05);1 a局部控制率分别为77.3%和50.0%(P<0.05);1 a无复发生存率分别为72.7%和45.5%(P<0.05);1 a生存率分别为81.8%和54.5%(P<0.05)。2组毒副反应相似,患者均可耐受。结论周剂量紫杉醇对局部晚期食管癌放疗具有明显的增敏作用,能提高患者的局部控制率和生存率,且毒副反应未明显增加。 Objective To evaluate the radiosensitizing effect of weekly-dose paclitaxel on locally advanced e- sophageal carcinoma. Methods Forty-four patients with unresectable locally advanced esophageal carcinoma were randomized into the radiosensitization group (22 patients) and the simple radiotherapy group (22 patients). All the patients were given with the same radiotherapy ( routine fractionation radiotherapy, DT 60-66 Gy). The 22 patients in the radiosensitization group were treated with radiotherapy combined with weekly-dose paclitaxel 40 mg · m-2 for 6 weeks, the 22 patients in the simple radiotherapy group were treated with radiotherapy alone. Results All the 44 patients could be evaluated, the response rates were 86.4% and 63.6% of the radiosensitization group and the sim- ple radiotherapy group ( P 〈 0.05 ) ; the 1 -year local control rates were 77.3% and 50.0% ( P 〈 0.05 ) ; the 1 -year failure-free survival rates were 72.7% and 45.5% ( P 〈 0.05) ; the 1-year survival rates were 81.8% and 54.5% ( P 〈 0.05 ). The toxicities of the radiosensitization group were similar to those of the simple radiotherapy group, and were tolerated. Conclusion Weekly-dose paclitaxel potently enhances the effect of radiotherapy in the treatment of locally advanced esophageal carcinoma, and can significantly improve the local control rate and the survival rate, and don't increase toxicities.
出处 《肿瘤基础与临床》 2012年第6期489-492,共4页 journal of basic and clinical oncology
关键词 周剂量 紫杉醇 食管癌 放疗 同步放化疗 weekly-dose paclitaxel esophageal carcinoma radiotherapy concurrent chemoradiotherapy
  • 相关文献

参考文献10

  • 1Enzinger PC ,Mayer RJ. Esophageal cancer [ J ]. N Engl J Med,2003, 349 (23) :2241 - 2252.
  • 2Kranzfelder M, Buchler P, Lange K, et al. Treatment options for squamous cell cancer of the esophagus : a systematic review of the literature [ J ]. J Am Coll Surg ,2010,210 ( 3 ) :351 - 359.
  • 3Wong RK, Malthaner RA, Zuraw L, et al. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus : a practice guideline [ J ]. Int J Radiat Oncol Biol Phys, 2003,55 ( 4 ) : 930 - 942.
  • 4Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone inpatients with esophageal cancer: an intergroup study [ J ]. J Clin Oncol, 1997,15 ( 1 ) : 277 - 284.
  • 5Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial( RTOG 85-01 ) [ J ]. JAMA, 1999,281 ( 17 ) : 1623 - 1627.
  • 6Emi M, Hihara J, Hamai Y, et al. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer [ J ]. Cancer Chemother Pharmaco1,2012,69 (6) : 1499 - 1505.
  • 7Eisterer W, DE Vries A, Kendler D, et al. Triple induction chemotherapy and chemoradiotherapy for locally advanced esophageal cancer: A phase Ⅱ study [ J ]. Anticancer Res, 2011,31 ( 12 ) : 4407 -4412.
  • 8Kato K, Muro K, Minashi K, et al. Phase Ⅱ study of chemoradio- therapy with 5-fluorouracil and cisplatin for Stage Ⅱ-Ⅲ esophageal squamous cell carcinoma : JCOG trial ( JCOG 9906) [ J ]. Int J Radiat Oneol B iol Phys,2011,81 (3) :684 - 690.
  • 9Stahl M, Budach W, Meyer HJ, et al. Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up [ J ]. Ann Oncol,2010,21 Suppl 5 :v46 - v49.
  • 10Orditura M, Galizia G, Napolitano V, et al. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase Ⅱ study [J]. Cancer Invest ,2010,28 (8) :820 - 827.

同被引文献38

引证文献6

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部